134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

原文始发于微信公众号(药时代):134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

正文共:70114
预计阅读时间:18分钟

药时代编者按:

2019年8月26日,全球著名的生物技术公司安进Amgen纳斯达克股票代码:AMGN)宣布已与著名的新基Celgene,纳斯达克股票代码:CELG)达成协议,安进将以134亿美元现金收购新基的Otezla®(apremilast,阿普斯特)的全球权利以及某些相关资产和负债。Otezla®是迄今为止治疗牛皮癣和银屑病关节炎的唯一一款口服的非生物制剂药品。扣除预期未来现金税收益的22亿美元,交易价值的净值或约112亿美元。
2019年1月3日,美国制药巨头百时美施贵(Bristol-Myers Squibb)宣布,将以740亿美元的价格收购新基公司。此次新基出让Otezla®以争取赢得反垄断监管机构美国联邦贸易委员会批准740亿美元收购案。

740亿美元!百时美施贵宝将收购新基

虚惊一场!百时美施贵宝收购新基得到股东鼎立支持!

Otezla®是一款全球知名的重磅炸弹,2018年全球销售额为16.1亿美元。安进预计Otezla的全球销量在未来五年内的增长速度为低两位数。
了解详情,请阅读下方新闻稿。
药时代将继续密切关注,及时报道。

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

THOUSAND OAKS, Calif.,Aug. 26, 2019/PRNewswire/ —Amgen(NASDAQ: AMGN) announced today that it has entered into an agreement withCelgene Corporation(NASDAQ: CELG) in connection with its previously announced merger withBristol-Myers Squibb Company(NYSE: BMY) to acquire worldwide rights to Otezla®(apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for$13.4 billionin cash, or approximately$11.2 billion, net of the present value of$2.2 billionin anticipated future cash tax benefits.Amgenbelieves that the acquisition of Otezla offers many benefits including:

  • A strong strategic fit withAmgen’slong-standing expertise in psoriasis and inflammation

  • A differentiated, oral therapy complementary toAmgen’sexisting inflammation franchise of innovative biologics and biosimilar products

  • At least low double-digit Otezla sales growth, on average, over the next five years

  • Acceleration ofAmgen’snear- and long-term revenue growth

  • Immediate non-GAAP EPS accretion

  • Intellectual Property exclusivity through at least 2028 in the U.S.

  • Worldwide rights which fit well withAmgen’sinternational presence and global expansion objectives

  • Support of increased R&D investment in 2020 to advanceAmgen’sinnovative pipeline of first-in-class molecules

  • No interruption in deployment ofAmgen’scapital allocation priorities

“The acquisition of Otezla offers a unique opportunity forAmgento provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits squarely within our portfolio and complements our Enbrel®and AMGEVITA®brands,” saidRobert A. Bradway, chairman and chief executive officer atAmgen. “We will take advantage of our 20 years of experience in inflammatory disease to realize the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions.”

Otezla is the leading treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S.—the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet’s Disease. Otezla is approved in more than 50 markets outside the U.S., including theEuropean UnionandJapan, and has patent exclusivity through at least 2028 in the U.S.

Sales of Otezla in 2018 were$1.6 billiondriven by strong volume growth.Amgenhas stated previously that it will focus on medicines that can deliver sustained, long-term volume driven growth and the Companybelieves there is a significant opportunity to grow Otezla through global expansion and new indications, with expectations for Otezla to realize at least low double-digit sales growth, on average, over the next five years.

Strategic Benefits of the TransactionThis transaction will advanceAmgen’sstrategy in several ways:

  • Bringing Innovative Medicines to Patients —The number of patients suffering from chronic inflammatory diseases is growing worldwide.

    Amgen is already a leader in this very large therapeutic category with Enbrel®(etanercept), a biologic medicine marketed byAmgen in the U.S. andCanada

    to treat several chronic inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe plaque psoriasis, and psoriatic arthritis (PsA). ENBREL and Otezla are complementary. ENBREL is most frequently prescribed to treat moderate-to-severe rheumatoid arthritis, while Otezla is positioned as a therapy of first-choice in patients with moderate-to-severe psoriasis who are not satisfied with topical therapies given its differentiated mechanism of action and established efficacy and safety profile. In PsA, Otezla is positioned for use in patients early in their disease and/or with moderate joint involvement. Additionally, studies are currently underway exploring potential new indications for Otezla, including mild-to-moderate psoriasis.

  • Expanding Geographic Reach— Otezla is approved in 54 countries, including major markets such as France, Germany andJapan.Amgenis well positioned to continue driving Otezla international sales growth.

  • Investing for Long-Term Growth with Uninterrupted Capital Allocation Plans— The transaction is expected to contribute to

    Amgen’s near- and long-term revenue growth rate and will be immediately accretive from close to non-GAAP earnings per share growth, with acceleration thereafter.Amgenwill finance the transaction with current balance sheet cash and expects to retain its investment grade credit rating. Additionally,Amgen’s

    capital allocation priorities will remain unchanged as we invest to grow our business through internal investment and business development, maintain an optimal capital structure to minimize our Weighted Average Cost of Capital and continue to provide capital returns to shareholders through a growing dividend and continued share repurchases.

The closing of the acquisition is contingent onBristol-Myers Squibbentering into a consent decree with theFederal Trade Commissionin connection with the pendingCelgenemerger, the closing of the pending merger withCelgeneand the satisfaction of other customary closing conditions. The transaction is expected to close by the end of 2019.

“Otezla represents an exciting opportunity to strengthenAmgen’spresence in inflammation and continueAmgen’sgeographic expansion,” said Bradway. “We are excited about the opportunity that Otezla represents forAmgen, for our shareholders, and for patients worldwide, and we look forward to welcoming those staff members who support Otezla to theAmgenfamily.”

Dyal Co. LLCis acting as the lead financial advisor toAmgen.Goldman Sachs & Co.is serving as a financial advisor andSullivan & Cromwell LLPis serving as legal advisor toAmgen.

AboutAmgenAmgenis committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgenfocuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980,Amgenhas grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visitwww.amgen.comand follow us onwww.twitter.com/amgen.

About OTEZLA®(apremilast)OTEZLA®(apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients is not well defined.
134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)
—— 推荐阅读!——

历史上首次!FDA局长就数据可靠性发表评论

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)
“大象”来了!印度制药军团”集结”,进军中国市场
Keytruda的故事
免疫力低到底是怎么回事?
天妒英才!珐博进(FibroGen)CEO Thomas B. Neff博士意外去世

诺华Sandoz新任CEO | 我爱仿制药,此生不渝!

惊喜发现!有一种蛋白,叫”哪吒”!

辉瑞普强与仿制药巨头Mylan合并(24页PPT)
里程碑!Vertex任命首位女总裁兼CEO

科创板咨询委委员、肿瘤专家李进:谁能成为中国的“华为制药”?

药时代,聚焦新药研发,荟萃行业精华,分享交流合作,共筑健康天下!

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

欢迎联系我们!

电话:17811879657;邮箱:drugtimes@qq.com;微信: 27674131

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部
134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特) | 药时代

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

原文始发于微信公众号(药时代):134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

正文共:70114
预计阅读时间:18分钟

药时代编者按:

2019年8月26日,全球著名的生物技术公司安进Amgen纳斯达克股票代码:AMGN)宣布已与著名的新基Celgene,纳斯达克股票代码:CELG)达成协议,安进将以134亿美元现金收购新基的Otezla®(apremilast,阿普斯特)的全球权利以及某些相关资产和负债。Otezla®是迄今为止治疗牛皮癣和银屑病关节炎的唯一一款口服的非生物制剂药品。扣除预期未来现金税收益的22亿美元,交易价值的净值或约112亿美元。
2019年1月3日,美国制药巨头百时美施贵(Bristol-Myers Squibb)宣布,将以740亿美元的价格收购新基公司。此次新基出让Otezla®以争取赢得反垄断监管机构美国联邦贸易委员会批准740亿美元收购案。

740亿美元!百时美施贵宝将收购新基

虚惊一场!百时美施贵宝收购新基得到股东鼎立支持!

Otezla®是一款全球知名的重磅炸弹,2018年全球销售额为16.1亿美元。安进预计Otezla的全球销量在未来五年内的增长速度为低两位数。
了解详情,请阅读下方新闻稿。
药时代将继续密切关注,及时报道。

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

THOUSAND OAKS, Calif.,Aug. 26, 2019/PRNewswire/ —Amgen(NASDAQ: AMGN) announced today that it has entered into an agreement withCelgene Corporation(NASDAQ: CELG) in connection with its previously announced merger withBristol-Myers Squibb Company(NYSE: BMY) to acquire worldwide rights to Otezla®(apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for$13.4 billionin cash, or approximately$11.2 billion, net of the present value of$2.2 billionin anticipated future cash tax benefits.Amgenbelieves that the acquisition of Otezla offers many benefits including:

  • A strong strategic fit withAmgen’slong-standing expertise in psoriasis and inflammation

  • A differentiated, oral therapy complementary toAmgen’sexisting inflammation franchise of innovative biologics and biosimilar products

  • At least low double-digit Otezla sales growth, on average, over the next five years

  • Acceleration ofAmgen’snear- and long-term revenue growth

  • Immediate non-GAAP EPS accretion

  • Intellectual Property exclusivity through at least 2028 in the U.S.

  • Worldwide rights which fit well withAmgen’sinternational presence and global expansion objectives

  • Support of increased R&D investment in 2020 to advanceAmgen’sinnovative pipeline of first-in-class molecules

  • No interruption in deployment ofAmgen’scapital allocation priorities

“The acquisition of Otezla offers a unique opportunity forAmgento provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits squarely within our portfolio and complements our Enbrel®and AMGEVITA®brands,” saidRobert A. Bradway, chairman and chief executive officer atAmgen. “We will take advantage of our 20 years of experience in inflammatory disease to realize the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions.”

Otezla is the leading treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S.—the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet’s Disease. Otezla is approved in more than 50 markets outside the U.S., including theEuropean UnionandJapan, and has patent exclusivity through at least 2028 in the U.S.

Sales of Otezla in 2018 were$1.6 billiondriven by strong volume growth.Amgenhas stated previously that it will focus on medicines that can deliver sustained, long-term volume driven growth and the Companybelieves there is a significant opportunity to grow Otezla through global expansion and new indications, with expectations for Otezla to realize at least low double-digit sales growth, on average, over the next five years.

Strategic Benefits of the TransactionThis transaction will advanceAmgen’sstrategy in several ways:

  • Bringing Innovative Medicines to Patients —The number of patients suffering from chronic inflammatory diseases is growing worldwide.

    Amgen is already a leader in this very large therapeutic category with Enbrel®(etanercept), a biologic medicine marketed byAmgen in the U.S. andCanada

    to treat several chronic inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe plaque psoriasis, and psoriatic arthritis (PsA). ENBREL and Otezla are complementary. ENBREL is most frequently prescribed to treat moderate-to-severe rheumatoid arthritis, while Otezla is positioned as a therapy of first-choice in patients with moderate-to-severe psoriasis who are not satisfied with topical therapies given its differentiated mechanism of action and established efficacy and safety profile. In PsA, Otezla is positioned for use in patients early in their disease and/or with moderate joint involvement. Additionally, studies are currently underway exploring potential new indications for Otezla, including mild-to-moderate psoriasis.

  • Expanding Geographic Reach— Otezla is approved in 54 countries, including major markets such as France, Germany andJapan.Amgenis well positioned to continue driving Otezla international sales growth.

  • Investing for Long-Term Growth with Uninterrupted Capital Allocation Plans— The transaction is expected to contribute to

    Amgen’s near- and long-term revenue growth rate and will be immediately accretive from close to non-GAAP earnings per share growth, with acceleration thereafter.Amgenwill finance the transaction with current balance sheet cash and expects to retain its investment grade credit rating. Additionally,Amgen’s

    capital allocation priorities will remain unchanged as we invest to grow our business through internal investment and business development, maintain an optimal capital structure to minimize our Weighted Average Cost of Capital and continue to provide capital returns to shareholders through a growing dividend and continued share repurchases.

The closing of the acquisition is contingent onBristol-Myers Squibbentering into a consent decree with theFederal Trade Commissionin connection with the pendingCelgenemerger, the closing of the pending merger withCelgeneand the satisfaction of other customary closing conditions. The transaction is expected to close by the end of 2019.

“Otezla represents an exciting opportunity to strengthenAmgen’spresence in inflammation and continueAmgen’sgeographic expansion,” said Bradway. “We are excited about the opportunity that Otezla represents forAmgen, for our shareholders, and for patients worldwide, and we look forward to welcoming those staff members who support Otezla to theAmgenfamily.”

Dyal Co. LLCis acting as the lead financial advisor toAmgen.Goldman Sachs & Co.is serving as a financial advisor andSullivan & Cromwell LLPis serving as legal advisor toAmgen.

AboutAmgenAmgenis committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgenfocuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980,Amgenhas grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visitwww.amgen.comand follow us onwww.twitter.com/amgen.

About OTEZLA®(apremilast)OTEZLA®(apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients is not well defined.
134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)
—— 推荐阅读!——

历史上首次!FDA局长就数据可靠性发表评论

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)
“大象”来了!印度制药军团”集结”,进军中国市场
Keytruda的故事
免疫力低到底是怎么回事?
天妒英才!珐博进(FibroGen)CEO Thomas B. Neff博士意外去世

诺华Sandoz新任CEO | 我爱仿制药,此生不渝!

惊喜发现!有一种蛋白,叫”哪吒”!

辉瑞普强与仿制药巨头Mylan合并(24页PPT)
里程碑!Vertex任命首位女总裁兼CEO

科创板咨询委委员、肿瘤专家李进:谁能成为中国的“华为制药”?

药时代,聚焦新药研发,荟萃行业精华,分享交流合作,共筑健康天下!

134亿美金!安进收购新基旗下银屑病药物Otezla®(阿普斯特)

欢迎联系我们!

电话:17811879657;邮箱:drugtimes@qq.com;微信: 27674131

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部